To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").
Active· Referred to the House Committee on Energy and Commerce.
Introduced
May 3, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending
Introduced
May 3, 22
Passed House
Pending
Passed Senate
Pending
Sent to President
Pending
Signed into Law
Pending
No roll call votes have been recorded for this bill.